Amit Khurana of Dolat Capital anticipates limited market movement in the coming quarter due to headwinds, suggesting a cooling period before renewed buying. Upside potential is capped, while downside risk is protected. He advises a neutral stance on the pharma sector for FY26, citing normalizing tailwinds and US trade tariffs, but favors JB, Ajanta, Cipla, and Torrent.
Ixigo shares jumps 14%, hits 52-week high after strong Q1 results
Ixigo Share Price: Ixigo’s shares soared after reporting strong Q1FY26 results, with revenue up 73% YoY to Rs 314.5 crore and net profit increasing 27%
July 17, 2025